Canada
· Delayed Price · Currency is CAD MariMed Statistics
Total Valuation
MariMed has a market cap or net worth of CAD 85.60 million. The enterprise value is 217.43 million.
| Market Cap | 85.60M |
| Enterprise Value | 217.43M |
Important Dates
The next estimated earnings date is Wednesday, November 6, 2024.
| Earnings Date | Nov 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
| Shares Outstanding | n/a |
| Shares Change (YoY) | +2.54% |
| Shares Change (QoQ) | +1.15% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 342.32M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.30, with an EV/FCF ratio of -73.86.
| EV / Earnings | -9.14 |
| EV / Sales | 1.00 |
| EV / EBITDA | 7.30 |
| EV / EBIT | 16.98 |
| EV / FCF | -73.86 |
Financial Position
The company has a current ratio of 1.30, with a Debt / Equity ratio of 1.00.
| Current Ratio | 1.30 |
| Quick Ratio | 0.46 |
| Debt / Equity | 1.00 |
| Debt / EBITDA | 4.10 |
| Debt / FCF | -40.70 |
| Interest Coverage | 1.24 |
Financial Efficiency
Return on equity (ROE) is -18.21% and return on invested capital (ROIC) is 3.35%.
| Return on Equity (ROE) | -18.21% |
| Return on Assets (ROA) | 2.89% |
| Return on Capital (ROIC) | 3.35% |
| Revenue Per Employee | 313,204 |
| Profits Per Employee | -34,872 |
| Employee Count | 721 |
| Asset Turnover | 0.78 |
| Inventory Turnover | 3.17 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -47.50% in the last 52 weeks. The beta is 2.80, so MariMed's price volatility has been higher than the market average.
| Beta (5Y) | 2.80 |
| 52-Week Price Change | -47.50% |
| 50-Day Moving Average | 0.23 |
| 200-Day Moving Average | 0.30 |
| Relative Strength Index (RSI) | 47.97 |
| Average Volume (20 Days) | 3,426 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.27 |
Income Statement
In the last 12 months, MariMed had revenue of CAD 213.61 million and -23.78 million in losses. Loss per share was -0.06.
| Revenue | 213.61M |
| Gross Profit | 92.43M |
| Operating Income | 12.58M |
| Pretax Income | -13.43M |
| Net Income | -23.78M |
| EBITDA | 26.43M |
| EBIT | 12.58M |
| Loss Per Share | -0.06 |
Balance Sheet
The company has 13.95 million in cash and 119.81 million in debt, giving a net cash position of -105.87 million.
| Cash & Cash Equivalents | 13.95M |
| Total Debt | 119.81M |
| Net Cash | -105.87M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 119.90M |
| Book Value Per Share | 0.25 |
| Working Capital | 16.96M |
Cash Flow
In the last 12 months, operating cash flow was 23.99 million and capital expenditures -26.94 million, giving a free cash flow of -2.94 million.
| Operating Cash Flow | 23.99M |
| Capital Expenditures | -26.94M |
| Free Cash Flow | -2.94M |
| FCF Per Share | n/a |
Margins
Gross margin is 43.27%, with operating and profit margins of 5.89% and -11.13%.
| Gross Margin | 43.27% |
| Operating Margin | 5.89% |
| Pretax Margin | -6.29% |
| Profit Margin | -11.13% |
| EBITDA Margin | 12.37% |
| EBIT Margin | 5.89% |
| FCF Margin | -1.38% |
Dividends & Yields
MariMed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.54% |
| Shareholder Yield | -2.54% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MariMed has an Altman Z-Score of 0.86. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.86 |
| Piotroski F-Score | n/a |